Cancer institute inks pact with Malaysia’s Abgentil for cutting-edge treatment, ET HealthWorld
Mumbai: A Thane-based cancer institute has signed an agreement with Malaysian pioneers Abgentil Biomedical SDN BHD to bring advanced and cutting-edge cancer treatment to India at an affordable cost. Under the agreement, SunAct Cancer Institute will introduce CAR-T, TCR, and TIL therapies for solid-state tumours in the country, the institute said in a statement.
“We are extremely happy that within a very short time of our inception, we have been able to bring this revolutionary cancer treatment for solid state tumours to India. Abgentil is a pioneer in the field of CAR-T, TCR, TIL and other innovative cancer therapies and this will give a lot of patients and their caregivers a lot of hope,” said SunAct founder and oncologist Dr Vijay Patil.
He said research indicates that most cancers diagnosed in the country are solid tumours, including head and neck cancers, breast cancer, and lung cancer.
“In situations where standard-approved therapies do not yield results, it is imperative that we consider alternative and innovative treatment options,” Dr Patil said.
He said adoptive cellular therapies, such as CAR-T, TCR, and TIL, represent a beacon of hope.
“Yet, access to these ground-breaking adoptive therapies remains a significant challenge in India,” he added.
Visit: Valley Vision News
